CR8439A - METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED - Google Patents

METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED

Info

Publication number
CR8439A
CR8439A CR8439A CR8439A CR8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A CR 8439 A CR8439 A CR 8439A
Authority
CR
Costa Rica
Prior art keywords
radio
improving
effectiveness
labeled
therapeutic drugs
Prior art date
Application number
CR8439A
Other languages
Spanish (es)
Inventor
Werner Krause
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CR8439A publication Critical patent/CR8439A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se dan a conocer drogas radiorotuladas y metodos para mejorar su eficacia mediante el uso de un radiosensibilizador tal que el radiosensibilizador tanto forma parte de la droga radiorotulada mediante el acople directo del rediosensibilizador a la droga radiorotulada como produciendo una mezcla de la droga radiorotulada y un analogo de la droga con el radiosensibilizador acoplado a la droga en lugar del radiorotuloRadio-labeled drugs and methods for improving their efficacy are disclosed through the use of a radiosensitizer such that the radiosensitizer is both part of the radio-labeled drug by direct coupling of the radio-sensitized rediosensitizer and producing a mixture of the radio-labeled drug and an analogue of the drug with the radiosensitizer coupled to the drug instead of the radio

CR8439A 2003-12-11 2006-06-07 METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED CR8439A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52847303P 2003-12-11 2003-12-11

Publications (1)

Publication Number Publication Date
CR8439A true CR8439A (en) 2006-12-07

Family

ID=34676848

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8439A CR8439A (en) 2003-12-11 2006-06-07 METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED

Country Status (14)

Country Link
EP (1) EP1691838A2 (en)
JP (1) JP2007528874A (en)
KR (1) KR20060118542A (en)
CN (1) CN101031319A (en)
AU (1) AU2004296621A1 (en)
BR (1) BRPI0417517A (en)
CA (1) CA2546057A1 (en)
CR (1) CR8439A (en)
EC (1) ECSP066618A (en)
IL (1) IL175674A0 (en)
MX (1) MXPA06006683A (en)
NO (1) NO20063207L (en)
RU (1) RU2006124510A (en)
WO (1) WO2005056058A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568453B (en) * 2011-11-22 2017-02-01 原創生醫股份有限公司 A drug carrier with chelating complex micelles and the application thereof
CN106975078B (en) * 2017-03-31 2020-11-10 国家纳米科学中心 Application of nano material containing gadolinium polytungstate as sensitizer
WO2024013272A1 (en) * 2022-07-13 2024-01-18 Universite De Montpellier Combined therapy with nanoparticles and radiopharmaceuticals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022404A1 (en) * 1999-01-25 2002-09-04 Photogen Inc METHOD AND AGENTS FOR IMPROVED RADIATION THERAPY
AU2001249608A1 (en) * 2000-03-28 2001-10-08 Beth Israel Deaconess Medical Center Bladder cancer-specific peptides for diagnosis and therapy
NZ527283A (en) * 2001-01-29 2006-03-31 Biogen Idec Inc Modified antibodies and methods of use
WO2004016753A2 (en) * 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
RU2006124510A (en) 2008-01-20
JP2007528874A (en) 2007-10-18
BRPI0417517A (en) 2007-03-06
NO20063207L (en) 2006-07-10
IL175674A0 (en) 2006-09-05
AU2004296621A1 (en) 2005-06-23
CN101031319A (en) 2007-09-05
MXPA06006683A (en) 2006-08-11
EP1691838A2 (en) 2006-08-23
CA2546057A1 (en) 2005-06-23
ECSP066618A (en) 2006-10-25
WO2005056058A2 (en) 2005-06-23
KR20060118542A (en) 2006-11-23
WO2005056058A3 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
GT200300245A (en) COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS
CL2015001891A1 (en) Enclosed controlled dose dosage forms resistant to tampering; use to treat pain; and method of preparation. (divisional of the application n ° 2754-2014).
TW200637614A (en) Bendamustine pharmaceutical compositions
AR048833A1 (en) PROCEDURE FOR THE TREATMENT OF PREMENSTRUAL DISORDERS AND OTHER FEMALE SEXUAL DISORDERS
AR049985A1 (en) COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES
HN2003000039A (en) 2- (PIRIMIDIN-2-ILAMINO) -PIRIDO [2,3-d] PIRIMIDIN-7-ONAS
ECSP055528A (en) PHARMACEUTICAL COMPOSITION THAT HAS A UNIFORM DISTRIBUTION AND POWER OF FARMACO
EA201001577A1 (en) DPP-4 INHIBITOR IN A COMBINATION WITH AN ADDITIONAL ANTI-DIABETIC AGENT, TABLETS INCLUDING THE SPECIFIED COMPOSITIONS, THEIR APPLICATION AND METHOD OF THEIR PRODUCTION
ATE432279T1 (en) TRICYCLIC DELTA OPIOID MODULATORS
MX2007010996A (en) Novel liposome compositions.
EA200600433A1 (en) CONJUGATED HETEROCYCLIC COMPOUNDS
CR20140108A (en) CYCLOPROPANOAMINE COMPOUND
ECSP099178A (en) METHOD OF TREATMENT OF THE ICTUS WITH A THROMBOLITIC
CR8380A (en) METHODS FOR PREPARING AND USING NEW DEVELOPMENTS OF MOTHER CELLS AND THEIR ASSEMBLIES
GT200500363A (en) 3-AMINO-PIRAZOL [3,4B] PIRIDINES WITH PROTEINTIROSINKINASE INHIBITORS, THEIR PREPARATION AND USE AS A MEDICINAL PRODUCT.
CR8519A (en) NEW FUSIONATED PIRROLOCARBAZOLS
UA94036C2 (en) Bendamustine pharmaceutical compositions for lyophilisation
AR032293A1 (en) PHARMACEUTICAL CASE
MX2008008413A (en) Pharmaceutical composition for the treatment of nail diseases.
CR8439A (en) METHOD FOR IMPROVING THE EFFECTIVENESS OF RADIO THERAPEUTIC DRUGS LABELED
BR0209645A (en) Oxazole and furopyrimidines and their use as medicines
DK1699480T3 (en) Allogeneic therapeutic tumor agent
Marcellin et al. Viral hepatitis: impressive advances but still a long way to eradication of the disease
PA8571401A1 (en) IMIDAZOLINILMETIL ARALQUILSULFONAMIDAS
CO2022017112A2 (en) N-cyanopyrrolidines with activity as ubiquitin-specific peptidase inhibitors 30